Optimal Strategy Unknown for Identifying Non-Lynch Syndrome Mutations in CRC
June 9th 2016Updated results of the prevalence of germline cancer susceptibility gene mutations in a clinic-based series of patients with colorectal cancer (CRC) were given in an oral presentation at the 2016 ASCO Annual Meeting.
Read More
Minimal Harm Associated with Multiplex Gene Testing for Inherited Cancer Risk
June 8th 2016Interim analysis of a clinical trial of multiplex gene testing for inherited cancer risk suggests that fears of unnecessary surgery or adverse psychological effects associated with testing may be unwarranted.
Read More
Targeting Molecular Abnormalities with Off-Label Indications
June 8th 2016An ongoing phase IIa basket study is evaluating treating patients who have molecular abnormalities with agents that target the HER2, BRAF, Hedgehog, or EGFR pathways, regardless of the patient's tumor type and the drug's original indication.
Read More
More CNS Adverse Events Associated With Enzalutamide Than Abiraterone/Prednisone Combo
June 7th 2016Patients with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with enzalutamide (Xtandi) were more likely to experience central nervous system (CNS) events or fatigue than patients treated with the combination of abiraterone acetate (Zytiga) and prednisone.
Read More
Safety Data Confirmed in Abiraterone, Low-Dose Prednisone Combo Trial
June 7th 2016Men with nmCRPC demonstrated a median time to PSA progression of 28.7 months and a median time to radiographic progression of 41.4 months, according to updated safety and efficacy data involving abiraterone acetate and low-dose prednisone.
Read More
Tumor Treating Fields Safe as Frontline Therapy in Unresectable Pancreatic Cancer
June 7th 2016A preliminary safety and efficacy trial of a device using tumor treating fields (TTF) administered to unresectable pancreatic cancer patients found that the treatment was tolerable and safe when combined with gemcitabine.
Read More
Lower Dose of Polatuzumab Active and Tolerable in Non-Hodgkin Lymphoma
June 9th 2015The 1.8-mg/kg dose of polatuzumab vedotin is as effective as the 2.4-mg/kg dose on the endpoint of progression-free survival in patients with relapsed/refractory non-Hodgkin lymphoma while improving tolerability, according to a pooled analysis of phase I and phase II clinical studies.
Read More
First Trial to Show Adjuvant Therapy Benefit in Prostate Cancer Revealed
June 5th 2015In the first phase III trial to show a benefit for adjuvant therapy in prostate cancer, treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival (OS) rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.
Read More
Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer
June 4th 2015Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with 131I-refractory differentiated thyroid cancer.
Read More
Ibrutinib Combination Significantly Reduces Progression in CLL
June 4th 2015The combination of ibrutinib with bendamustin plus rituximab (BR) demonstrated a significant improvement in progression-free survival compared with BR alone in patients with pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Cerdulatinib in Relapsed/Refractory B-Cell Malignancies
June 3rd 2015Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.
Read More
Lenvatinib in Thyroid Cancer With and Without VEGF-Targeted Therapy
June 2nd 2015Matthew H. Taylor, MD, Oregon Health and Science University, discusses the efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.
Read More
ASCO Study Supplies Targeted Therapies for Molecularly-Defined Patients
June 2nd 2015ASCO has revealed its first clinical trial, which will provide patients with limited options an opportunity to receive a potentially beneficial targeted therapy that matches their distinct genetic make-up and is FDA-approved for another type of cancer.
Read More
Study Shows First-Time Survival Benefit for Soft Tissue Sarcoma
June 2nd 2015Marking the first time a phase III study has shown a survival advantage for patients with soft tissue sarcoma, treatment with eribulin (Halaven) demonstrated improved overall survival (OS) by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
Read More
Adding Everolimus to Sorafenib Improves PFS by 14 Months in Refractory Differentiated Thyroid Cancer
June 1st 2015The addition of everolimus to sorafenib extended progression-free survival (PFS) in patients with metastatic differentiated thyroid carcinoma (DTC) that had progressed on sorafenib alone, according to findings from a single-arm open-label phase II study.
Read More
BRAF/MEK Combo Shows Overall Survival Benefit at 2 Years in Melanoma Patients
June 1st 2015Patients with BRAF-mutant late-stage melanoma derive a lasting overall survival (OS) benefit from treatment with the combination of dabrafenib and trametinib compared with dabrafenib and placebo, according to the final results from the COMBI-d phase III double-blinded trial.
Read More
Effect of Age and Lenvatinib on OS in Thyroid Cancer
May 31st 2015Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in the SELECT trial.
Read More
Novel JAK Inhibitor Reduces Spleen Volume and Symptoms in Myelofibrosis
May 31st 2015Compared with best available therapy, the novel JAK2 inhibitor pacritinib demonstrated significantly better outcomes in spleen volume reduction and symptom control when administered to patients with myelofibrosis.
Read More